We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move ...

The FDA has granted fast track designation to nadunolimab for use in combination with gemcitabine and nab-paclitaxel to treat patients with previously untreated, metastatic PDAC with high IL1RAP ...

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer ...

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer ...

Early diagnosis and treatment of pancreatic cancer offer the best odds of beating the disease. Unfortunately, there is still no screening test, such as a blood test, that can reliably detect ...

lumc.nl Background Pathogenic variants in the CDKN2A gene are generally associated with the development of melanoma and pancreatic ductal adenocarcinoma (PDAC), but specific genotype-phenotype ...

Other, less common types of pancreatic cancer may differ. For example, squamous adenocarcinoma of the pancreas is associated with very poor outcomes, and neuroendocrine tumors tend to have a better ...

Furthermore, SPT is positive for claudin-18.2and claudin-7 in a few cases, and pancreatic endocrine tumor (PET), acinar cell carcinoma(ACC), and pancreatoblastoma (PB) show strong expression of ...

has granted Fast Track Designation for EBC-129 for the treatment of pancreatic ductal adenocarcinoma (PDAC). EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, ...

The Fast Track Designation highlights the potential of EBC-129 to address critical unmet needs in pancreatic ductal adenocarcinoma (PDAC). Updated clinical data from the ongoing Phase 1 study of ...